Stockreport

MindMed doses first subject in trial of tablets for generalised anxiety disorder [Yahoo! Finance]

Catalent, Inc.  (CTLT) 
Last catalent, inc. earnings: 2/3 07:30 am Check Earnings Report
US:NYSE Investor Relations: investor.catalent.com
PDF The first of two Phase III trials, Voyage is designed to assess the therapy's safety and efficacy versus placebo among nearly 200 US subjects. It will be carried out [Read more]